New gene switch activates with simple skin patch and could help treat diabetes
ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch ...
EMBO Press1d
LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
BioPharma Dive2d
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...
Gene editing approach sheds light on how mitochondria drive autophagy
Autophagy is the process by which cells digest and renew their internal structures, recycling damaged or malfunctioning ...
eLife5d
Maturation and detoxification of synphilin-1 inclusion bodies regulated by sphingolipids
Due to proteostasis stress induced by aging or disease, misfolded proteins can form toxic intermediate species of aggregates and eventually mature into less toxic inclusion bodies (IBs). Here, using a ...
Taiwan News15d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Basel, 31 January 2025 - Roche (SIX ... tissue samples. The PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ...
EuropaWire15d
Roche Expands FDA Approval of PATHWAY® HER2 Test for HER2-Ultralow Breast Cancer Status
(PRESS RELEASE) BASEL, 1-Feb-2025 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label for its PATHWAY® anti ...
MarketWatch15d
Roche: FDA Approved Label Expansion for PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Seeking Alpha15d
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG released its Q4 and full-year 2024 earnings yesterday. I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS ...
Yahoo Finance15d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Basel, 31 January 2025 - Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ENHERTU compared to 8 ...
Yahoo Finance15d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
With the introduction of HER2-low and now HER2-ultralow classifications, Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free ...